Sandbox Reserved 1073: Difference between revisions
No edit summary |
No edit summary |
||
| Line 29: | Line 29: | ||
== Clinical Applications == | == Clinical Applications == | ||
[[Image:Isoniazid.JPG|thumb|350px|right|Figure 5. Isoniazid Mechanism of Action]] | |||
=== Isoniazid === | === Isoniazid === | ||
Isoniazid is a first-line antibiotic that has been used to treat tuberculosis infections for over 50 years. Isoniazid is known to inhibit mycolic acid biosnthesis, which is the function of InhA. The activated form of isoniazid is covalently attached to the [http://en.wikipedia.org/wiki/Nicotinamide nicotinamide] ring of NADH. However, Isoniazid is still not an ideal antibiotic because many drug-resistant strains of tuberculosis have shown resistance to this inhibitor. Specifically, the mutation Ser<sup>94</sup> to Ala of InhA was sufficient enough to have isoniazid resistance. | Isoniazid is a first-line antibiotic that has been used to treat tuberculosis infections for over 50 years. Isoniazid is known to inhibit mycolic acid biosnthesis, which is the function of InhA. The activated form of isoniazid is covalently attached to the [http://en.wikipedia.org/wiki/Nicotinamide nicotinamide] ring of NADH. However, Isoniazid is still not an ideal antibiotic because many drug-resistant strains of tuberculosis have shown resistance to this inhibitor. Specifically, the mutation Ser<sup>94</sup> to Ala of InhA was sufficient enough to have isoniazid resistance. | ||